WE CLAIM:

1. A dry powder pharmaceutical suspension composition suitable for use as a liquid suspension, the composition comprising granules that include cefuroxime axetil, at least one lubricant, and at least one glidant.

2. The composition of claim 1 wherein the composition exhibits better bioavailability as compared to Ceftin® oral suspension.

3. The composition of claim 1 wherein the composition is free of food effects.

4. The composition of claim 1 wherein the cefuroxime axetil comprises up to about 99.89% by weight of the granules.

5. The composition of claim 1 wherein the lubricant comprises one or more of stearic acid, calcium stearate, sodium stearyl fumarate and combinations thereof.

6. The composition of claim 1 wherein the lubricant comprises from about 0.01% to about 10% by weight of the granules.

7. The composition of claim 1 wherein the glidant comprises one or more of colloidal silicon dioxide and talc.

8. The composition of claim 1 wherein the glidant comprises about 0.1% to about 5% by weight of the granules.

9. The composition of claim 1 wherein the composition further comprises one or more of suspending agents/viscosity enhancers, buffering agents, fillers, wetting agents, preservatives, flavouring agents, and sweeteners.

10. The composition of claim 9 wherein the suspending agent/viscosity enhancer comprises one or more of cellulosic derivatives, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, sodium carboxymethylcellulose, gums, xanthan gum, guar gum; polysaccharides, starch, pregelatinised starch, alginates, sodium alginate; acrylic acid copolymers, carbopols, polyvinylpyrrolidone, and combinations thereof.

11. The composition of claim 9 wherein the buffering agent comprises one or more of monosodium citrate, sodium citrate, citric acid, and combinations thereof.

12. The composition of claim 9 wherein the filler comprises one or more of sucrose, starch, lactose, microcrystalline cellulose, and combinations thereof.

13. The composition of claim 9 wherein the wetting agent comprises one or more of sodium lauryl sulphate, polysorbates, tween 40, tween 60, tween 80, poloxamer, and combinations thereof.

14. The composition of claim 9 wherein the preservative comprises one or more of methyl paraben, propyl paraben, sodium benzoate, and combinations thereof.

15. The composition of claim 9 wherein the flavouring agents/sweeteners comprise one or more of grenadine flavour, tutti frutti flavour, peppermint flavour, aspartame, saccharine sodium, sucrose, sorbitol, sodium cyclamate and combinations thereof.

16. The composition of claim 1 wherein the granules comprise up to approximately 315 mg of cefuroxime axetil per 5 ml of suspension, up to approximately 6 mg of colloidal silicon dioxide per 5 ml of suspension, and up to approximately 6 mg of stearic acid per 5 ml of suspension.

17. The composition of claim 9 wherein the composition comprises approximately 3979 mg of sucrose per 5 ml of suspension, approximately 20 mg of aspartame per 5 ml of suspension, approximately 84 mg of silicon dioxide per 5 ml of suspension, approximately 10 mg of monosodium citrate per 5 ml of suspension, approximately 19 mg of flavour per 5 ml of suspension, and approximately 10 mg of sodium chloride per 5 ml of suspension.

18. A process of forming a dry powder pharmaceutical suspension composition suitable for use as a liquid suspension, the process comprising forming granules by granulating a mixture of cefuroxime axetil, at least one lubricant, and at least one glidant by compaction/slugging.

19. The process of claim 18 further comprising sizing the granules.

20. The process of claim 18 wherein the granules are prepared by compaction.

21. The process of claim 18 wherein the cefuroxime axetil comprises up to about 99.89% by weight of the granules.

22. The process of claim 18 wherein the lubricant comprises one or more of stearic acid, calcium stearate, sodium stearyl fumarate, and combinations thereof.

23. The process of claim 18 wherein the lubricant comprises from about 0.01% to about 10% by weight of the granules.

24. The process of claim 18 wherein the glidant comprises one or more of colloidal silicon dioxide and talc.

25. The process of claim 18 wherein the glidant comprises from about 0.1% to about 5% by weight of the granules.

26. The process of claim 18 further comprises mixing one or more additional pharmaceutical excipients with the granules.

27. The process according to claim 25 wherein the additional pharmaceutical excipients comprise one or more of suspending agents/viscosity enhancers, buffering agents, fillers, wetting agents, preservatives, flavouring agents and sweeteners.

28. A method of dosing for infections treated with cefuroxime axetil, the method comprising administering a dry powder pharmaceutical suspension composition of cefuroxime axetil dissolved or suspended in an ingestible liquid, the composition comprising granules that include cefuroxime axetil, at least one lubricant, and at least one glidant.